AcelaBio (US) Inc. obtains accreditation from the College of American Pathologists (CAP)

SAN DIEGO, September 16, 2022/PRNewswire/ — AcelaBio (US) Inc., a contract research organization providing precision medicine and histopathology laboratory services for global clinical trials, has achieved accreditation by the College of American Pathologists (CAP). CAP accreditation indicates that the laboratory meets strict requirements for quality, accuracy, and consistency of test results to ensure optimal evaluation of patient diagnoses and outcomes. It also ensures that the laboratory meets the standards of the Clinical Laboratory Improvement Amendments (CLIA), the United States Food and Drug Administration (FDA), and the Occupational Safety and Health Administration (OSHA), since the requirements of the CAP commonly exceed those standards. The CAP assessment is performed according to discipline-specific checklists that include the latest best practices to ensure that the laboratory follows rapidly evolving changes in laboratory medicine and technology.

As a CAP-accredited laboratory, AcelaBio has rigorous policies and procedures for assay optimization and validation to ensure high-quality laboratory testing and patient safety. A documented audit trail is generated for each sample that arrives at AcelaBio and is tracked throughout the workflow in a laboratory information system.

“Our mission is to improve understanding of disease mechanisms and support the development of safe and effective treatments for patients. Earning CAP accreditation is internationally recognized as a symbol of quality. This accreditation solidifies the value we bring to our partners and customers by supporting global multicenter clinical trials with precision medicine and histopathology laboratory services,” explained Dr. Niels Vande CasteeleAssociate Professor of Medicine at the University of California in San Diego and president of AcelaBio.

For more information, contact

related links

About AcelaBio (US) Inc.

AcelaBio is a state-of-the-art contract research organization providing end-to-end precision medicine and histopathology laboratory services for pharmaceutical, biotech and academic institutions.

AcelaBio provides high-throughput digital pathology services to support global multi-center clinical trials and has the flexibility to develop and validate biomarker assays for new or existing protein or molecular targets. AcelaBio’s laboratory capabilities are applicable to a wide range of therapeutic indications, including gastroenterology, oncology and dermatology. AcelaBio is highly specialized in analyzing gastrointestinal tissues from patients with inflammatory bowel diseases (for example, Crohn’s disease and ulcerative colitis), eosinophilic gastrointestinal diseases (for example, eosinophilic esophagitis), and liver diseases (non-alcoholic steatohepatitis). AcelaBio employs operational, scientific, and medical experts, including US Board-Certified Pathologists, dedicated to providing high-quality, reliable data and images.

About the College of American Pathologists (CAP)

As the The world’s largest organization of board-certified pathologists and a leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and championing excellence in the practice of pathology and laboratory medicine. all over the world. For more information, read CAP’s Annual Report at

Niels Vande Casteele, Tel: 858-345-5932, E-mail:

AcelaBio (US) Inc. obtains accreditation from the College of American Pathologists (CAP)